2025年1月1日至2025年12月31日。 2025年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 证券代码：688185 证券简称：康希诺 公告编号：2026-002 康希诺生物股份公司 （一）业绩预告期间 （二）业绩预告情况 1、经康希诺生物股份公司（以下简称"公司"）财务部门初步测算，预计2025年年度（以下简称"报告 期"）实现营业收入104,000.00万元到108,000.00万元，与上年同期相比，将增加19,366.19万元到 23,366.19万元，同比增长22.88%到27.61%。 2、预计2025年年度实现归属于母公司所有者的净利润为2,450.00万元到2,900.00万元，与上年同期相 比，将实现扭亏为盈。 3、预计2025年年度实现归属于母公司所有者扣除非经常性损益后净利润为-9,100.00万元到-9,600.00万 元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 公司2024年年度实现营业收入为84,633.81万元，利润总额为 ...

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Group 1 - The Nipah virus outbreak in India has raised concerns, particularly in West Bengal, but its impact on China is considered minimal as no cases have been reported in the country [1] - The market has shown increased interest in stocks related to virus prevention and diagnostics, with companies like Capbio and Da'an Gene experiencing significant stock price increases [1] - The Nipah virus has a transmission period of 3 to 14 days, with initial symptoms resembling influenza, making early detection crucial for effective intervention [1] Group 2 - Several A-share listed companies have announced their developments in Nipah virus detection technologies, including Wanfu Bio and Shengxiang Bio, which have launched various testing kits [3][5] - Capbio has developed a Nipah virus nucleic acid detection kit, providing essential support for global quarantine and disease control monitoring [5] - Some companies, such as Hualan Vaccine and Yirui Bio, have clarified that they do not have any products related to Nipah virus prevention or treatment [5][6]

北京商报讯（记者 丁宁）1月27日晚间，康希诺（688185）发布2025年业绩预告显示，预计2025年实现 归属净利润为2450万元到2900万元，与上年同期相比，将实现扭亏为盈。 康希诺表示，报告期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价 流脑结合疫苗曼海欣收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控；产销 协同进一步优化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属净利润为正。同 时，报告期内，随着公司研发项目的快速推进及国际合作的开展，公司获得了更多政府专项补助及国际 专项资金的支持，故于报告期产生较大金额的非经常性收益。 ...

Core Viewpoint - The company is advancing its candidate product development as planned and will share updates on progress when available [1] Group 1: R&D Progress - The company is actively progressing its candidate product research and development [1] - Updates on any significant advancements will be communicated to stakeholders [1] Group 2: Business Expansion - The company is leveraging its mRNA platform to expand related business opportunities [1] - A three-component LNP delivery system has been authorized for external use and supports other partners in research and development [1] - The company is collaborating with domestic and international partners to further enhance the application and value of its platform [1]

证券日报网讯 1月27日，康希诺在互动平台回答投资者提问时表示，公司以在世界范围内提供预防和治 疗感染类疾病的解决方案为己任，已建立了成熟的技术平台，可以针对不同病毒及细菌等的防护需要进 行疫苗的开发。公司会持续关注该事件及其发展，在评估相关事件发展情况、开发效率及投入、市场空 间及经济效益测算等因素后，如有必要会考虑后续步骤。公司会积极履行社会及国际责任，愿为全球公 共卫生事业作出贡献。 ...

Group 1 - Zhenray Technology expects a net profit increase of 530%-642% in 2025, driven by growth in satellite communication and special integrated circuit demand [10][11] - Ganfeng Lithium anticipates a net profit of 1.1 billion to 1.65 billion yuan in 2025, marking a turnaround from a loss of 2.074 billion yuan in the previous year [12][13] Group 2 - Yingxin Development plans to acquire 60% of Changxing Semiconductor for 520 million yuan, aiming to enhance its business structure and mitigate operational risks [2] - Xinda Securities will have 2.551 billion shares released for trading on February 2, 2026, which constitutes 78.67% of its total share capital [2] Group 3 - *ST Boda forecasts a net profit of 6 million to 8 million yuan for 2025, but expects a loss of 4.5 million to 6.5 million yuan when excluding non-recurring items [3] - Dongcai Technology's actual controller is under investigation, which may impact the company's operations [4] Group 4 - Aisen Co. plans to invest 2 billion yuan in a semiconductor materials manufacturing base in East China, with production expected to start in 2028 [6] - Beixin Road and Bridge has won a project worth 1.221 billion yuan for road construction, with a duration of 1096 days [7] Group 5 - Pizaihuang has initiated a Phase I clinical trial for its innovative drug PZH2113, targeting non-Hodgkin lymphoma, with no similar drugs approved globally [8][9] - Muxi Co. expects a revenue of 1.6 billion to 1.7 billion yuan in 2025, despite a projected loss of 650 million to 798 million yuan [9] Group 6 - New Guodu anticipates a net profit of 400 million to 500 million yuan in 2025, reflecting a growth of 70.79%-113.49% [12] - Yahua Group expects a net profit of 600 million to 680 million yuan in 2025, an increase of 133.36%-164.47% [12] Group 7 - Hunan Huasheng anticipates a net profit of 2.4 billion to 3 billion yuan in 2025, a significant reduction in losses compared to the previous year [17] - Cloud From Technology expects a loss of 490 million to 590 million yuan in 2025, despite revenue growth [18] Group 8 - Shennan Circuit expects a net profit increase of 68%-78% in 2025, driven by demand in AI computing and storage markets [19] - Chengdu Xiandao forecasts a net profit of 1.04 billion to 1.27 billion yuan in 2025, reflecting a growth of 102.5%-147.29% [21] Group 9 - Guodian Quantum anticipates a net profit of around 5 million yuan in 2025, marking a return to profitability [26] - Xiamen Tungsten expects a net profit of 2.311 billion yuan in 2025, a 35.08% increase year-on-year [27]

（文章来源：证券日报） 证券日报网讯 1月27日，康希诺发布公告称，公司预计2025年年度实现营业收入104000.00万元到 108000.00万元，与上年同期相比，将增加19366.19万元到23366.19万元，同比增长22.88%到27.61%；预 计实现归属于母公司所有者的净利润为2450.00万元到2900.00万元，与上年同期相比，将实现扭亏为 盈。 ...

金马游乐：2025年净利润同比预增811.17%-1069.56% 1月27日晚，金马游乐(300756)发布业绩预告，预计2025年归属于上市公司股东的净利润为6700万-8600 万元，比上年同期增长811.17%-1069.56%。 诺德股份：对1.5万吨生产线进行技术改造 1月27日晚，诺德股份(600110)发布公告称，拟对全资子公司青海电子材料产业发展有限公司二厂1.5万 吨生产线设备实施更新改造，项目总投资估算为1.68亿元。改造完成后，生产线将具备4.5微米及以下高 端锂电铜箔的量产能力，以应对下游客户在高端产品领域的需求。 楚江新材：2025年净利润同比预增60.97%-95.78% 1月27日晚，楚江新材(002171)发布业绩预告，预计2025年归属于上市公司股东的净利润为3.70亿-4.50亿 元，比上年同期增长60.97%-95.78%。 八方股份：2025年净利润同比预增40.96%–72.29% 1月27日晚，八方股份(603489)发布业绩预告，预计2025年度实现归属于上市公司股东的净利润为9000 万元到1.1亿元，与上年同期相比，同比增长40.96%到72.29%。 艾森 ...

智通财经APP讯，康希诺(688185.SH)发布2025年年度业绩预告，预计2025年年度实现归属于母公司所 有者的净利润为2,450万元到2,900万元，与上年同期相比，将实现扭亏为盈。 报告期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗 曼海欣®收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控;产销协同进一步 优化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属于母公司所有者的净利润为 正。 ...